Antengene brings first ATG-207 preclinical data to EULAR 2026 as autoimmune focus deepens
Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.
Pharma & Biotech
Pharma & Biotech
Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?
UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.
Medical Devices & Diagnostics
What KORU Medical’s RYSTIGGO delivery clearance means for subcutaneous infusion models
KORU Medical’s FreedomEDGE gets FDA clearance for RYSTIGGO delivery in clinics. Find out how this expands access to gMG therapy and reshapes infusion workflows.
Pharma & Biotech
How Staccato technology positions Lee’s Pharmaceutical for CNS drug delivery leadership
Lee’s Pharmaceutical Holdings Limited has acquired the Staccato One Breath Technology platform and related assets from Alexza Pharmaceuticals, gaining exclusive rights to manufacture and license Staccato alprazolam under its global agreement with UCB. The transaction expands Lee’s Pharmaceutical’s inhalation drug delivery pipeline, deepens its foothold in central nervous system therapies, and positions the company to